A Phase 1, Randomized, Double-Blind, Placebo-Controlled, 3-Part Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Dose ALN-HSD in Healthy Adult Subjects and Multiple Dose ALN-HSD in Adult Patients With Nonalcoholic Steatohepatitis (NASH)
Latest Information Update: 20 May 2024
At a glance
- Drugs ALN-HSD (Primary)
- Indications Non-alcoholic steatohepatitis
- Focus Adverse reactions; Therapeutic Use
- Sponsors Alnylam Pharmaceuticals
Most Recent Events
- 06 Mar 2024 Status changed from completed to discontinued due to business reasons and changes in the development strategy of the product and not for any safety issues.
- 15 Feb 2024 Status changed from active, no longer recruiting to completed.
- 17 Nov 2023 Planned End Date changed from 29 May 2024 to 21 Dec 2023.